Gilde Healthcare
en nl de
  • Portfolio
  • Team
  • News
  • About us
  • Contact

News 2016

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Follow @GildeHealthcare

Moximed: First Patient Treated in US Study of Atlas® System for Unicompartmental Knee Osteoarthritis

November 29, 2016 – Shock Absorber for the Knee Targets Patients Who Are Seeking Alternatives to Joint Replacement HAYWARD, Calif. – Moximed®, Inc. announced today that the first patient has been treated in an FDA-approved IDE study for its latest generation unicompartmental unloading implant, the Atlas…

Related to: Moximed

ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients

October 27, 2016 – Topline data to be presented today at NACFC LEIDEN, the Netherlands (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that clinical study PQ-010-002, a proof-of-concept study of nasal potential difference (NPD), demonstrated that QR-010 restored CFTR function…

Related to: ProQR Therapeutics

Sanifit announces initiation of first clinical trial of SNF472 in patients with calciphylaxis

October 20, 2016 – San Diego, USA and Palma, Spain - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced successful initiation of the first clinical trial of its lead candidate, SNF472, for the treatment of the orphan…

Related to: Sanifit

STAT-Diagnostica Attracts Siemens Venture Capital as a New Investor

October 5, 2016 – Funding will be used to support go-to-market activities in Europe BARCELONA – Medical diagnostics company STAT-Diagnostica has closed an extension of its Series C financing with Siemens Venture Capital. The additional proceeds will be used to support the 2017 European launch of its…

Related to: STAT-Dx QIAGEN

Acacia Pharma announces positive Phase 3 results in post-operative nausea and vomiting

August 12, 2016 – Acacia Pharma announces positive results from a pivotal Phase 3 trial of BAREMSIS™ for the treatment of post-operative nausea and vomiting BAREMSIS now shown to treat PONV, as well as prevent it Cambridge, UK – Acacia Pharma Group plc ("Acacia Pharma"), the supportive care company…

Related to: Acacia Pharma

Gilde Healthcare participates in $93 million equity round for cardiovascular company CVRx

August 11, 2016 – Equity Offering to Support Heart Failure Trial and European Commercial Expansion Minneapolis – CVRx, Inc., a private medical device company, has announced an equity financing totaling $93 million. Gilde Healthcare participated in the financing alongside existing investors, Johnson…

Related to: CVRx

Gilde Healthcare leads USD 20 million financing round of Belgian sleep therapy company Nyxoah

July 7, 2016 – Board will be strengthened with industry experts and Enrique Vega appointed as new CEO Mont-Saint-Guibert, Belgium – Nyxoah S.A., a medical device company focused on developing a neurostimulation based, disruptive therapy for patients suffering from Obstructive Sleep Apnea (OSA),…

Related to: Nyxoah

Gilde Healthcare participates in EUR 12.5 million round of Dutch sleep apnea scale-up NightBalance

July 5, 2016 – NightBalance raises EUR 12.5 million to support the commercial roll-out of the Sleep Position Trainer in Europe and the U.S. Supervisory Board and Management team strengthened with industry experts Delft, the Netherlands – NightBalance BV, a leading innovator of obstructive sleep…

Related to: NightBalance

Gilde Healthcare closes oversubscribed €250 million ($285 million) later stage and growth capital fund

June 14, 2016 – New fund targets innovative scale-up opportunities in medtech, digital health and therapeutics Utrecht, The Netherlands and Cambridge, Massachusetts – Gilde Healthcare, the European specialist investment firm, today announces the final close of Gilde Healthcare IV, a €250 million…

Sanifit appoints Preston S. Klassen MD, MHS as Chief Medical Officer and announces new US Subsidiary

June 7, 2016 – Former Head of R&D at Orexigen Therapeutics and Therapeutic Area Head for Nephrology at Amgen appointed as CMO CMO appointment and launch of US subsidiary are significant steps in establishing a US presence Palma de Mallorca, Spain - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical…

Related to: Sanifit

Moximed’s Atlas™ Knee System Improves Pain Scores and Returns Function to Pre-Arthroplasty Patients with Medial Knee Osteoarthritis

May 9, 2016 – Results from Multi-center, Prospective Study with Unicompartmental Joint Unloading Device for the Knee Presented at ESSKA / Moximed Commercializing Atlas System in Europe

Related to: Moximed

Agendia's MammaPrint® First and Only Genomic Test to Receive Level 1A Clinical Utility Evidence for Chemotherapy Benefit in Early Breast Cancer Patients

April 19, 2016 – Agendia, Inc. announced that using the company's MammaPrint® assay, patients with early-stage breast cancer who were considered at high risk for disease recurrence based on clinical and biological criteria can avoid chemotherapy.

Related to: Agendia

Symphogen Initiates Anti-MET Clinical Program

April 12, 2016 – And Presents Pre-Clinical Anti-MET Data at Annual AACR Meeting April 18th in New Orleans

Related to: Symphogen

Gilde Healthcare leads EUR 25 million financing round of Medical Diagnostics company STAT-Diagnostica

April 11, 2016 – Medical diagnostics company STAT-Diagnostica has closed a Series C financing round totaling EUR 25 million. The proceeds will be used to prepare for the 2017 European launch of its DiagCORE Near Patient Testing system.

Related to: STAT-Dx QIAGEN

Acacia Pharma initiates second pivotal Phase 3 treatment study with BAREMSIS™ (APD421) in post-operative nausea & vomiting (PONV)

March 21, 2016 – Acacia Pharma Group announces the initiation of its second pivotal Phase 3 treatment study, investigating BAREMSIS™ in surgical patients who develop post-operative nausea & vomiting, despite having received antiemetic prophylaxis before surgery.

Related to: Acacia Pharma

NIZO food research and Gilde Healthcare join forces for growth

March 7, 2016 – Ede, The Netherlands - NIZO food research, an international contract research organization (CRO) for companies active in food and healthcare markets, announces today that Gilde Healthcare has joined as a shareholder to facilitate long term growth. Jasper van Gorp, Managing Partner…

Related to: NIZO

Inova Labs acquired by ResMed

January 12, 2016 – SAN DIEGO, Calif. – ResMed (NYSE:RMD), a leading innovator in sleep-disordered breathing and respiratory care, today announced it has entered into a definitive agreement to acquire Inova Labs Inc., a privately-held medical device company specializing in the development and commercialization…

Related to: Inova Labs

Acacia Pharma announces positive results from second pivotal Phase 3 study of BAREMSIS™ (APD421) in prevention of post-operative nausea & vomiting

January 6, 2016 – Cambridge, UK – Acacia Pharma Group plc, the supportive care company developing products for US and international markets, announces positive results from a Phase 3 study investigating BAREMSIS™ (amisulpride injection, formerly APD421) in combination with standard antiemetics for…

Related to: Acacia Pharma

Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology

January 4, 2016 – Partnership aims to advance development of novel immune checkpoint therapies as Baxalta expands oncology leadership in orphan diseases Symphogen to receive $175 million (€160 million) upfront, in addition to potential future milestone payments and royalties BANNOCKBURN, Ill. and…

Related to: Symphogen

Gilde Healthcare

Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare's venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare's private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.

Investment Philosophy

Gilde Healthcare invests in fast growing, innovative businesses delivering better care at lower cost.

  • Home
  • Portfolio
  • Team
  • News
  • Contact
  • Imprint
  • Privacy Policy